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BY-NC-ND license (http://creativecomBackground/Purpose: Extracorporeal membrane oxygenation (ECMO) is a treatment option for
stabilizing neonates with congenital diaphragmatic hernia (CDH) in a critical condition when
standard therapy fails. However, the use of this approach in Taiwan has not been previously
reported.
Methods: The charts of all neonates with CDH treated in our institute during the period 2007
e2014 were reviewed. After 2010, patients who could not be stabilized with conventional
treatment were candidates for ECMO. We compared the demographic data of patients with
and without ECMO support. The clinical course and complications of ECMO were also reviewed.
Results: We identified 39 neonates with CDH with a median birth weight of 2696 g (range, 1526
e3280 g). Seven (18%) of these patients required ECMO support. The APGAR score at 5 minutes
differed significantly between the ECMO and non-ECMO groups. The survival rate was 84.6%
(33/39) for all CDH patients and 57.1% (4/7) for the ECMO group. The total ECMO bypass times
in the survivors was in the range of 5e36 days, whereas all nonsurvivors received ECMO for atave no conflicts of interest relevant to this article.
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j.jfma.2016.06.012least 36 days (mean duration, 68 days). Surgical bleeding occurred in four of seven patients in
the ECMO group.
Conclusion: The introduction of ECMO rescued some CDH patients who could not have survived
by conventional management. Prolonged (i.e., > 36 days) ECMO support had no benefit for sur-
vival.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
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nc-nd/4.0/).Introduction
Congenital diaphragmatic hernia (CDH) is a severe congenital
anomalywith an incidence of approximately one case in every
2000e5000 live births.1 The degree of pulmonary hypoplasia
and pulmonary hypertension determines the severity of the
disease, as well as survival in patients with CDH.2e4 In addi-
tion, early stabilization of the patient is a priority before un-
dertaking surgical intervention for the herniated organ.
Hence,management of perinatal pulmonary hypertension is a
critical focus in the current treatment of CDH.
In 1975, Bartlett et al5 reported the first successful use of
extracorporeal membrane oxygenation (ECMO) in newborns
with cardiopulmonary failure. This technique was soon
applied to CDH neonates with severe respiratory distress to
provide preoperative stabilization.6e8 The use of ECMO in
CDH neonates, which is widely reported in the USA, has long
been debated. A Cochrane review on its use for severe res-
piratory failure in infants failed to demonstrate a clear
survival benefit for neonates with CDH, although many sur-
geons in the USA and Europe consider ECMO as a treatment
option.9 The experience of using ECMO for neonatal CDH has
rarely been reported in Asia10e12 and has never been re-
ported in Taiwan.
Since 1994, the National Taiwan University Hospital, Tai-
pei, Taiwan has used ECMO as a means of mechanical cir-
culatory support for adults and neonates.13 In December
1994, the first neonatal ECMO treatment was applied to a
newborn that could not be separated from cardiopulmonary
bypass after cardiac surgery. However, it was not until 2007
that we successfully used ECMO to treat a neonatal patient
with respiratory failure in our hospital. In 2010, we first used
ECMO for a patient with CDH. In this paper, we report our
experience using ECMO for neonates with CDH and the out-
comes of these patients, with and without ECMO support.Methods
Patients
The 39 CDH neonates who were treated at the National
Taiwan University Hospital (Taipei, Taiwan) from 2007 to
2014 were all included in this study. The demographic data,
medical treatment, surgical timing, operative findings, and
outcome of the patients with CDH were collected via chart
review. The ECMO indication, parameters of the ECMO run,
and complications of ECMO were prospectively collected
for quality assurance.14ng W-T, et al., Extracorporeal mem
e in Taiwan, Journal of the FoManagement of patients with CDH
After delivery, the neonatal patients were admitted to the
neonatal intensive care unit. Infants who presented with
respiratory distress were stabilized using standard medical
and ventilator therapy. If conventional ventilator therapy
failed, high-frequency oscillatory ventilation (HFOV) and
inhaled nitric oxide (iNO) were applied to patients with
severe pulmonary hypertension.
Indications for ECMO
Our indications for ECMO were: (1) an oxygenation index of
 40; (2) an alveolarearterial oxygen difference> 610mmHg
for 8 hours or an alveolarearterial oxygen diffe-
rence > 600 mmHg for 12 hours; or (3) partial pressure of
arterial oxygen < 40 mmHg for 2 hours. The decision about
consultation for ECMO cannulation was made by the neo-
natologists caring for the infant.
The ECMO technique
We used venoearterial ECMO for the first run because of he-
modynamic instability.Cannulationwasperformedbythecut-
down method through the internal jugular vein and common
carotid artery.15 The ECMO circuit consisted of a centrifugal
pump and a hollow-fiber membrane oxygenator with an inte-
grated heat exchanger (Medtronic, Inc., Anaheim, CA, USA),
and all surfaces were heparin-bound. The ECMO blood flow
was generally maintained between 80 mL/kg/min and
120 mL/kg/min. Patients underwent anticoagulation treat-
ment with heparin to achieve an activated clotting time goal
of 160e180 seconds. In patients with excessive bleeding, we
lowered the goal or temporarily ceased administering the
anticoagulant. We did not use aprotinin or antifibrinolytic
agents during ECMO. Platelets were transfused to keep the
platelet count above 50,000/mm3, and red blood cells were
generally transfused to maintain a hematocrit between 35%
and 40% during ECMO use.14
The timing and technique of surgical repair for CDH
In our first ECMO case, we surgically repaired the CDH on
the 8th day of the ECMO run and observed a tendency for
bleeding during the operation. In the subsequent cases, we
changed our policy to perform CDH repair early, provided
that stable ECMO flow was established (usually within
72 hours of ECMO). We used a transabdominal approach forbrane oxygenation for neonatal congenital diaphragmatic hernia:
rmosan Medical Association (2016), http://dx.doi.org/10.1016/
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closed using nonabsorbable interrupted sutures or a poly-
tetrafluoroethylene patch (Gore-Tex patch; W. L. Gore and
Associates, Newark, DE, USA) if direct repair was
impossible.Patent ductus arteriosus ligation
If chest radiography showed persistent pulmonary conges-
tion and echocardiography revealed a large patent ductus
arteriosus (PDA) with a left-to-right shunt a few days after
the surgical repair, we performed PDA ligation (n Z 4/7
infants).Weaning off ECMO
After surgical repair of the CDH, the decision to wean the
patient off ECMO was based on the patient’s cardiac and
pulmonary status. Inotropic agents were then tapered.
Improved lung compliance and a clear lung field on plain
chest X-ray were mandatory before a trial of weaning off
ECMO.Statistical analysis
Statistical analyses were performed using the JMP version
9.0 statistical package (SAS Institute Inc., Cary, NC, USA).
The Wilcoxon rank-sum test was used to compare numerical
variables, and Fisher’s exact test was used to compare
nominal variables between the ECMO and non-ECMO patientTable 1 Demographic characteristics of all congenital diaphrag
Total ECMO
Demographics
N (%)a 39 (100) 7 (17.9)
Malea 22 (56.4) 3 (42.9)
GA (wks) (< 37)b 36.7  2.0 (38.5) 35.9  3.
BBW (g)c 2696 (24553026) 2560 (218
APGAR at 5 mind 7.6  1.5 6.9  0.9
Left sidea 34 (87.2) 6 (85.7)
Liver upa 13 (34.2) 1 (14.3)
LHRd,e 1.78  0.5 1.57  0.
Patch repaira 8 (21.1) 1 (14.3)
HFOVa 21 (53.8) 7 (100)
iNOa 10 (25.6) 7 (100)
Survantaa 2 (5.1) 2 (28.6)
Outcome
Survivala 33 (84.6) 4 (57.1)
Days in hospitald 45.1  50.3 99  67.5
*Indicates statistical significance.
BBWZ birth body weight; CDHZ congenital diaphragmatic hernia; E
age; HFOV Z high-frequency oscillatory ventilation; iNO Z inhaled n
SD Z standard deviation.
a Data are presented as n (%).
b mean  SD (%).
c median (IQR), or
d mean  SD.
e Only four ECMO patients and 10 non-ECMO patients had lungehea
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Results
Among the 39 newborns with CDH, 22 (56.4%) were male
and 15 (38.5%) were premature. The demographic data are
summarized in Table 1. In 27 (69%) patients, the diagnosis
of CDH was based on prenatal sonography. All recorded
lunghead ratios (LHRs) in this series (14 of 34 infants)
were > 1. We administered antenatal steroids only for
anticipated premature delivery, regardless of the LHR.
Among the 39 neonates with CDH, seven (18%) were
treated using ECMO. The APGAR score at 5 minutes after
birth was significantly higher in the non-ECMO group. There
was no significant difference between the ECMO and non-
ECMO groups in terms of gestational age, birth body weight,
side of the lesion, liver herniation, and prenatal LHR. All
patients in the ECMO group received HFOV and iNO for
persistent pulmonary hypertension, before being placed on
extracorporeal life support. In contrast, in the non-ECMO
group, only 43.8% of the infants received HFOV and 9.4% of
the infants received iNO. Only one (2.6%) patient had a
congenital heart disease (i.e., coarctation of the aorta)
other than PDA or atrial septal defect.
The pre-ECMO condition and parameters during the
ECMO run are presented in Table 2. The median birth body
weight was 2560 g for the ECMO-supported patient, and the
lowest weight was only 1668 g. Two patients (#3 and #7) had
undergone cannulae insertion and ECMO initiation in other
hospitals, either by our ECMO transport team or by the
referring team, and were then transported to our intensivematic hernia patients with or without ECMO support.a
Non-ECMO p
32 (82.1)
19 (59.4) 0.680
0 (57.1) 36.9  1.7 (34.4) 0.359 (0.400)
03080) 2710 (25313024) 0.410
7.8  1.6 0.030*
28 (87.5) 1.000
12 (38.7) 0.390
3 1.86  0.6 0.524
7 (22.6) 1.000
14 (43.8) 0.010*
3 (9.4) <0.001*
0 (0) 0.030*
29 (90.6)
33.3  37.8 0.0004*
CMOZ extracorporeal membrane oxygenation; GAZ gestational
itric oxide; IQR Z interquartile range; LHR Z lunghead ratio;
d ratio data.
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Table 2 Clinical and ECMO profiles of patients with congenital diaphragmatic hernia with ECMO support.
Patient no. Sex GA
(wks)
BBW
(g)
APGAR
(1’ > 5’)
LHR Pre-ECMO ECMO run parameters
AaDO2 OI Age at 1
st cannulation Total bypass days
#1 F 33 þ 3 2450 4 > 7 1.76 619 111 1 d 36
#2 F 31 1668 5 > 7 1.67 608 47 8 d 105
#3 M 38 þ 2 3330 5 > 6 NA 631 55 < 24 h 6
#4 M 36 þ 4 2560 4 > 6 1.1 603 54 < 24 h 37
#5 F 36 þ 2 2180 5 > 6 NA 618 55 < 24 h 62
#6 M 37 þ 2 2610 5 > 8 1.75 625 36 1 d 18
#7 F 40 3080 7 > 8 NA 603 50 2 d 5
AaDO2: alveolarearterial oxygen difference; BBW Z birth body weight; CDH Z congenital diaphragmatic hernia;
ECMO Z extracorporeal membrane oxygenation; F Z female; GA Z gestational age; HFOV Z high-frequency oscillatory ventilation;
iNO Z inhaled nitric oxide; LHR Z lunghead ratio; M Z male; OI: oxygenation index.
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within 48 hours of birth, before the surgical repair of the
CDH. The other patient (#2) required ECMO support 7 days
after the CDH repair. All patients received ECMO in the
venoearterial mode when undergoing their first run of
ECMO. Three patients (#1, #4, and #6) required a second
run of ECMO. The median total ECMO bypass times were
36 days (range, 5e105 days). The mean ECMO bypass time
was significantly longer for the nonsurvivors than for the
survivors (68.0  34.4 days and 16.3  14.4 days,
respectively).
All patients who were cannulated before the hernia
repair, except for the first patient, underwent surgical repair
within 2 days of the initiation of ECMO. The size of the defect
varied; however, only one defect was repaired by a poly-
tetrafluoroethylene surgical patch (Gor-Tex patch; W. L.
Gore and Associates). Chest tubes were inserted during theTable 3 Surgical repair, bleeding complications, and outcome
Patient no. CDH repair
Timing of
repair after
cannulation
Side Defect size
(cm)
Patch repair
#1 8 d L 5  3 N
#2 7 dc L 5  4 N
#3 1 d L NA N
#4 1 d L 3  3 N
#5 1 d L 6.5  3.5 Y
#6 2 d L 4  3 N
#7 1 d R 4.5  4.5 N
BiPAP Z bilevel positive airway pressure; CDH Z congenital diaphr
ICH Z intracranial hemorrhage; IVH Z intraventricular hemorrhage;
a Surgical bleeding is defined as hemothorax/hemopericardium o
reopening for hemostasis.
b Medical bleeding is defined as IVH or ICH, confirmed by brain ech
c CDH repair was performed 7 days before ECMO cannulation.
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j.jfma.2016.06.012operation in four patients. The other three patients, who did
not have chest tube insertion during the operation, still
required chest tube insertion subsequently because of
hemothorax. Five (71%) patients experienced major
bleeding complications, such as hemothorax, intracranial
hemorrhage, or intraventricular hemorrhage during ECMO
use. The PDA was ligated in four (57.1%) patients (Table 3).
The overall survival rate was 84.6% (33/39) for all CDH
patients. The survival rate was 57.1% (4/7) for the ECMO-
supported patients and 90.6% (29/32) for the non-ECMO
patients. In the ECMO group, one survivor (patient #6)
required long-term support by bilevel positive airway
pressure treatment after discharge. The other three survi-
vors were able to breathe without ventilator support. Of
the three mortalities, all were premature (gestational age,
< 37 weeks). ECMO was withdrawn in two patients because
they showed no improvement under prolonged support andin the ECMO group.
Bleeding
complication
Outcome
Chest tube
Insertion
Surgicala Medicalb
Y N N Survival to discharge
N Y IVH, ICH Severe ICH, ECMO
withdrawal, expired
N Y d Survival to discharge
Y N d Pneumonia-induced
respiratory failure
after weaning ECMO,
expired
Y Y IVH No recovery, ECMO
withdrawal, expired
N Y ICH Discharge with long-
term BiPAP
Y N IVH Survival to discharge
agmatic hernia; ECMO Z extracorporeal membrane oxygenation
N Z no; Y Z yes.
n the involved side that requires chest tube (re-)insertion or
o or computed tomography.
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as massive intracerebral hemorrhage. The other patient
developed pneumonia-induced fatal respiratory failure
11 days after weaning off ECMO.
In the non-ECMO group, two of the three nonsurvivors
died due to infection and unresolved pulmonary hyperten-
sion at the ages of 129 days and 224 days, respectively. The
remaining patient was suspected of having had an associ-
ated tracheoesophageal fistula and could not survive at the
initial resuscitation after birth. These three nonsurvivors
were potential candidates for extracorporeal life support,
whereas none of the surviving patients ever met the in-
dications for ECMO.
Discussion
Survival and severity of CDH
In our experience, the survival rate among all CDH patients
was 84.6%. This result was comparable to the findings of
other institutions (69e93%).2,16,17 We noted a low preva-
lence of comorbid major cardiac diseases in our cases [1/39
(2.6%) infants], as compared to the 10.6% prevalence re-
ported by the Congenital Diaphragmatic Hernia Study Group
(CDHSG).18 We also noted the absence of patients with an
LHR < 1, which represents severe pulmonary hypoplasia,
compared to 10% of patients with an LHR < 1 in a Japanese
study.11
Percentage of ECMO use
The use of ECMO in CDH neonates is widely reported in the
USA.7,8,19 According to the CDHSG report, 34% (1063/3100)
of patients with CDH were managed by ECMO support be-
tween 1995 and 2004.20 However, the frequency of ECMO
use varies widely among centers, and ranges between 11%
and 61%.17 In Asia, the experience of ECMO application in
neonates with CDH has not been widely reported. In a
Japanese nationwide survey,10,11 only 7% (43/614) of pa-
tients with CDH underwent ECMO between 2006 and 2010.
Our frequency of ECMO use (7/39, 17.9%) is lower than that
of the USA and higher than that of Japan. The latter may be
due to the presence of dedicated multidisciplinary clinics
for such patients, with staff trained to optimize ECMO
management after a preliminary learning period.
The outcome of ECMO
Our survival rate in the ECMO group (57.1%) was comparable
with other reports. For infants with isolated CDH, the re-
ported overall survival ranged from 33e86%.17 In the CDHSG
study, the survival rate in the ECMO-supported group was
48% for the entire cohort and 61% for patients who under-
went surgical repair.20 The previous Japanese study re-
ported a survival rate of 37.2% (16/43 patients) for CDH
patients with ECMO support.10 In the pre-ECMO era at our
hospital, a study performed from 1985 to 1998 showed that
CDH neonates with an oxygen index of more than 40 all
died, despite HFOV support and gentle ventilation ther-
apy.15 In the current series, with the introduction of ECMO,Please cite this article in press as: Hung W-T, et al., Extracorporeal mem
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j.jfma.2016.06.012we observed a survival benefit in patients with CDH who
were refractory to conventional treatment. This finding is
consistent with the CDHSG report that ECMO significantly
improved survival in CDH neonates with a high mortality
risk.21
In our study, the APGAR score at 5 minutes correlated
significantly with the use of ECMO, while gestational age,
birth body weight, and prenatal LHR did not. Our small
sample size may have limited the detection of significant
differences. The available literature is unfortunately
insufficient to answer the question of potential correlations
with other variables definitively, because of the retro-
spective nature of such studies. The weaknesses of avail-
able studies include unequal numbers between groups, no
control for the patients’ illness levels, and the use of his-
torical controls.Duration of ECMO
The mean duration of ECMO treatment in our study was
long, especially in the nonsurvivor group (mean,
68.0  34.4 days; longest duration:, 105 days). The pro-
portion of patients in whom prolonged ECMO treatment was
used (i.e.,  21 days) was high [4/7 (57%) infants]. By
comparison, in the CDHSG report, the mean ECMO bypass
duration was only 9  6 days for survivors and 15  8 days
for nonsurvivors.20 The percentage of patients in whom
prolonged ECMO support is used is generally < 30%.22 In a
Japanese report, for isolated CDH patients who could sur-
vive or did not survive more than 90 days, the median
duration of ECMO was 5 days (range, 1e13 days) and
8.5 days (range, 1e47 days), respectively.10 The adequate
ECMO duration for the most severe CDH remains unknown.
Sufficient improvement in pulmonary function that would
allow weaning a patient off ECMO could take 4 weeks or
longer.22 However, it has been noted that a longer duration
of ECMO is a strong predictor of a poor outcome.20
In our experience, none of the CDH patients who
required ECMO support for longer than 36 days survived. A
similar finding was reported in a study23 based on the
Extracorporeal Life Support Organization registry data from
1998 to 2011, in which the mortality of neonates with res-
piratory failure who were on ECMO support for longer than
43 days was 100%. In Taiwan, the cost of ECMO for CDH has
been reimbursed by the National Health Insurance scheme
since 2009. The markedly prolonged use of ECMO in our
patients, compared to its use in other countries, may
reflect the unlimited reimbursement by the National Health
Insurance. However, the unlimited duration of ECMO use
does not provide a survival benefit, while it may increase
health care costs and extend the suffering for the patient
and the family.24 Our longest survivor on ECMO was an adult
drowning patient who experienced acute respiratory
distress syndrome after hospitalization and was supported
for 117 days,25 but the pathogenesis of acute respiratory
distress syndrome and of CDH differ markedly. The possi-
bility of recovery for CDH patients is altogether worth
waiting for over 6 weeks of ECMO use. However, we could
not find a successful experience of neonatal respiratory
failure in which ECMO support was performed for more than
6 weeks. Based on current experience, for those CDHbrane oxygenation for neonatal congenital diaphragmatic hernia:
rmosan Medical Association (2016), http://dx.doi.org/10.1016/
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treatments other than ECMO, such as palliative care should
be considered.
Complications of ECMO
Bleeding is a major complication of ECMO use, with a re-
ported high incidence of 43% or more, and may lead to
death in up to 4.8% of patients.26 A major concern is
intraoperative bleeding during CDH repair. In three of our
first six patients with ECMO support, we noted a bleeding
tendency during the surgery and decided to place chest
tubes intraoperatively. However, the other three patients
who did not undergo chest tube insertion during surgery
experienced hemothorax after the operation and required
bedside chest tube insertion or reoperation for hemostasis.
It is widely accepted that prophylactic chest tube place-
ment is not needed for CDH repair if there is no active
bleeding.16 A high risk of surgical site bleeding was noted in
our patients on ECMO support. Severe bleeding with sub-
sequent tension hemothorax could further lead to cardio-
pulmonary compromise. In this situation, emergent
thoracotomy or chest tube insertion adds an extra surgical
risk under systemic anticoagulation for ECMO.27 Therefore,
after our seventh patient, we routinely inserted a chest
tube after the CDH repair for neonates undergoing ECMO
support.
PDA ligation
The role of PDA in the management of pulmonary hyper-
tension in patients with CDH has not been discussed pre-
viously. Left-to-right shunting through the ductus arteriosus
results in pulmonary overcirculation and pulmonary edema,
decreases lung compliance, and may exacerbate pulmonary
hypertension. If the pulmonary edema does not improve
under venoearterial ECMO support and use of diuretics,
persistent flow from the PDA is considered clinically
important. However, because of the complicated disease
status and multiple contributing factors, we could not
observe consistent clinical improvement in our limited
experience.
Timing of repair
In our first ECMO case, we performed surgical repair of
CDH on the 8th day of the ECMO run and noted a bleeding
tendency during the operation. In the following cases, we
changed our policy to perform early CDH repair provided
that a stable ECMO flow was established (usually within
72 hours of ECMO). The literature contains several reports
comparing “early” and “late” repair on ECMO; it appears
that patients undergoing early repair have significantly
fewer complications than those undergoing late repair.28
Regardless of the optimal timing, there remains a role
for surgical repair when a patient is on ECMO. Published
data are discordant since the CDHSG registry showed a
statistically significant difference in the proportional
hazard of death (hazard ratio Z 1.41; 95% confidence in-
terval, 1.031.92; p Z 0.03) when comparing surgical
repair on ECMO with that after ECMO decannulation.29Please cite this article in press as: Hung W-T, et al., Extracorporeal mem
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vival and reduced operative morbidity in patients with
CDH undergoing repair after decannulation.30 By contrast,
recent reports have further complicated these data, and
suggest a potential benefit to early repair (within 72 hour)
on ECMO. Due to these confounding results which are
based on limited data, many institutions utilize different
protocols, such as weaning the patient over the course of
approximately 1 week prior to surgery on ECMO or sug-
gesting a delayed repair close to the planned dec-
annulation date. In our institute, we prefer early surgical
repair (< 72 hours) after cannulation, considering the
possibility of prolonged ECMO support and the increased
risk of intraoperative bleeding when the ECMO duration
increases.
Study limitations
This study was based on a single-institute experience. The
case number was small and our findings may only represent
a preliminary learning period. Improvement and standard-
ization of the perioperative care were not considered in the
analysis.
Conclusion
In conclusion, this is the first study on the use of ECMO in
neonates with CDH in Taiwan. The introduction of ECMO
rescued some CDH patients who could not have survived
by conventional management. However, we had no sur-
vivors after 36 days of ECMO support. We may consider
routine chest tube insertion during CDH repair on ECMO
support because of the high risk of postoperative
bleeding.
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